NASDAQ:KTTA

Pasithea Therapeutics Q3 2026 Earnings Results & Report

Pasithea Therapeutics logo
$0.43 -0.07 (-13.14%)
Closing price 04:00 PM Eastern
Extended Trading
$0.43 0.00 (-0.07%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pasithea Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$0.20 versus the -$0.21 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

Pasithea Therapeutics EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.21
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 4 quarters

Pasithea Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$200 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Pasithea Therapeutics Q3 2026 Earnings FAQ

Pasithea Therapeutics (NASDAQ:KTTA) reported earnings of -$0.20 per share for Q3 2026, beating the consensus estimate of -$0.21. The report was announced on Friday, November 13, 2026.

Pasithea Therapeutics Earnings Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Pasithea Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pasithea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pasithea Therapeutics and other key companies, straight to your email.

About Pasithea Therapeutics

Pasithea Therapeutics (NASDAQ:KTTA) is a clinical-stage biotechnology company developing therapies for serious diseases. Its current focus is PAS-004, a next-generation macrocyclic MEK inhibitor being studied for conditions associated with the RAS/MAPK signaling pathway, including neurofibromatosis type 1.

The company’s research has shifted over time: Pasithea previously focused on treatments for neurological and psychiatric disorders. Its current development efforts are centered on PAS-004 and potential applications in diseases with limited treatment options.

Pasithea is headquartered in the United States and is listed on the Nasdaq under the ticker KTTA.

View Pasithea Therapeutics Profile